GALDERMA 2024: Phase III trials of RelabotulinumtoxinA show favorable outcomes and extended effectiveness in addressing both glabellar lines and lateral canthal lines at once.

Aviceda Therapeutics Reveals Preliminary Results from Initial Segment of Phase 2/3 SIGLEC Study on AVD-104, Indicating Encouraging Safety Profile and Initial Efficacy Signals in Individuals with Geographic Atrophy.

Aruna Bio has received FDA approval for its investigational new drug (IND) application, allowing AB126, its pioneering exosome therapy.

Sarepta Therapeutics Launches Participant Selection for Phase 3 Trial, EMERGENE, Investigating SRP-9003 in Limb-Girdle Muscular Dystrophy 2E/R4 Treatment.

CARsgen's candidate, CT011, has secured authorization from the NMPA to proceed with trials for GPC3-positive Ⅲa hepatocellular carcinoma patients with a significant risk of recurrence post-surgery.

Halozyme Reports Roche Granted EU Clearance for Subcutaneous Form of Tecentriq® with ENHANZE® Technology, Marking a Breakthrough in the Delivery of Immunotherapies Across Various Cancers.

Chipscreen NewWay Initiates Phase 1 Study: Administers Initial Dose of Innovative Dual-Targeting Antibody NWY001 for Advancing Cancer Immune Therapy in Individuals with Progressive Solid Cancers.

InnoCare Pharma has disclosed that the FDA has given approval to proceed with the clinical study for its BCL2 inhibitor, designated as ICP-248.

AM-Pharma B.V. has started Phase 2 trials treating patients to test its enzyme, ilofotase alfa, for preventing kidney injury post-cardiac surgery.

ExeVir Bio reports its antibodies effectively neutralize current COVID-19 Omicron strains.

Hope Medicine Inc. announces successful completion of its Phase Ib "An Open-Label Study on Safety and Efficacy of HMI-115 in Androgenetic Alopecia over 24 Weeks," advancing its research milestones.

Indapta Therapeutics Reveals Initial Treatment of Patients Using IDP-023, a Non-Self Derived NK Cell Treatment for Cancer Management.